Cannabis Sprays for Chronic Pain: Lessons from 34 Individual Patient Trials
In 34 individual patient trials of sublingual cannabis extracts for chronic pain, THC-containing extracts were most effective, with a wide dose range needed and common but generally acceptable side effects.
Quick Facts
What This Study Found
Thirty-four patients with chronic, mainly neuropathic, pain used three cannabis-based sublingual sprays (THC, CBD, and 1:1 THC:CBD) over 12 weeks in individual randomized crossover trials. THC-containing extracts proved most effective for symptom control. A wide range of dosing requirements was observed across patients, and structured regimens for using the sublingual spray emerged from patient experience.
Side effects were common, reflecting a learning curve for both patients and the study team, but were generally acceptable and similar to those seen with other psychoactive medications used for chronic pain. The study established practical parameters for using cannabis-based medicines in pain management.
Key Numbers
Thirty-four patients studied individually over 12 weeks each. Three extract formulations tested. THC-containing extracts most effective. Wide dosing range observed. Side effects common but generally acceptable.
How They Did This
These were 34 individual "N of 1" trials using sublingual cannabis extracts. After an initial open-label period, the three extracts (THC, CBD, THC:CBD 1:1) were tested in randomized, double-blind, placebo-controlled crossover format over 12 weeks per patient.
Why This Research Matters
This study provided practical clinical experience with cannabis-based medicines that was crucial for the development of dosing guidelines. The finding that THC was the primary active ingredient for pain, and that a wide dose range was needed, influenced how Sativex was subsequently prescribed.
The Bigger Picture
These early clinical experiences with sublingual cannabis extracts directly informed the development and clinical use of Sativex. The individual patient trial design, while unusual, provided detailed data on tolerability and dosing that larger trials could not capture.
What This Study Doesn't Tell Us
N-of-1 trials, while rigorous for individual patients, have limited generalizability. The open-label period may have biased subsequent randomized periods. Side effects described as "common" raises questions about long-term tolerability.
Questions This Raises
- ?Why was CBD alone less effective for pain than THC?
- ?Could the wide dosing range be predicted by patient characteristics?
- ?How do these results compare to conventional pain medications?
Trust & Context
- Key Stat:
- THC-containing extracts most effective across 34 individual pain trials
- Evidence Grade:
- This is a series of randomized, blinded, individual patient trials providing moderate-level evidence with practical clinical detail.
- Study Age:
- Published in 2004. These early experiences directly informed the development of Sativex dosing guidelines.
- Original Title:
- Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.
- Published In:
- Anaesthesia, 59(5), 440-52 (2004)
- Authors:
- Notcutt, William(2), Price, Mario, Miller, Roy, Newport, Samantha, Phillips, Cheryl, Simmons, Susan, Sansom, Cathy
- Database ID:
- RTHC-00172
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Is THC or CBD better for pain?
In these trials, THC-containing extracts were most effective for chronic pain control. CBD alone was less effective for pain, though it may contribute to the overall effect when combined with THC.
Why do people need such different doses?
The wide dosing range observed reflects individual differences in cannabinoid metabolism, receptor sensitivity, pain severity, and tolerance. This is why cannabis-based medications typically require individual dose titration.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-patches-suppositories-topicals-explained
- cannabis-and-endometriosis-thc-pain
- cannabis-and-menstrual-cramps-period-pain
Cite This Study
https://rethinkthc.com/research/RTHC-00172APA
Notcutt, William; Price, Mario; Miller, Roy; Newport, Samantha; Phillips, Cheryl; Simmons, Susan; Sansom, Cathy. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.. Anaesthesia, 59(5), 440-52.
MLA
Notcutt, William, et al. "Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.." Anaesthesia, 2004.
RethinkTHC
RethinkTHC Research Database. "Initial experiences with medicinal extracts of cannabis for ..." RTHC-00172. Retrieved from https://rethinkthc.com/research/notcutt-2004-initial-experiences-with-medicinal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.